The following teaser is from a March 12, 2015 article posted at the Wall Street Journal website.
23andMe Inc., the personal genetics company, has sold enough DNA spit kits to accumulate genetic information on 850,000 customers. Now it plans to mine that database for drug targets, and it has picked a star drug developer to lead the effort.
The closely held Mountain View, Calif., company said Thursday that Richard Scheller, who retired in December as head of research and early development at Roche Holding AG, will become chief science officer next month and lead a new therapeutics group that will seek to discover new drugs.
…
Dr. Scheller’s appointment is the latest in a string of moves 23andMe has made to revamp operations since late 2013, when the U.S. Food and Drug Administration rebuked the company for aggressively marketing the saliva kits as a medical test…
